mepa8 Get alerts

Eugia recalls one lot of vancomycin 1.25 g vials nationwide after glass particle found

The single recalled lot shipped to wholesalers across the U.S. in September 2026, and the company says it has received no adverse event reports so far.

A generic glass medication vial for injection on a pharmacy or hospital counter, with no readable brand name and no people visible.
A pharmacy shelf displaying various medication vials at Kuks Hospital in Trutnov District. Photo: Jiří Sedláček / CC BY-SA 4.0

Key takeaways

  • Eugia US LLC, formerly Auro Medics Pharma LLC, is recalling one lot of Vancomycin Hydrochloride for Injection USP 1.25 g single-dose vials because a glass particle was found inside a vial.
  • The recall covers lot 3VM26026A with expiration JUL 2028, and extends to the hospital, healthcare facility and user level.
  • The company shipped the entire lot to wholesalers nationwide between September 2 and September 15, 2026.
  • Eugia says it has received no reports of adverse events tied to this recall as of the November 6, 2026 announcement.
  • For crews: the affected vials carry NDC 55150-471-01 on the vial label, NDC 55150-471-10 on the carton, and lot number 3VM26026A.

Eugia US LLC is recalling a single lot of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL single-dose vials after a glass particle was found inside a vial, according to a company announcement dated November 6, 2026, and posted by the U.S. Food and Drug Administration on November 9 [1]. The company, based in East Windsor, New Jersey, was formerly known as Auro Medics Pharma LLC [1].

The recall covers lot number 3VM26026A and reaches to the hospital, healthcare facility and user level [1]. The FDA record states that the recall is being conducted with the agency's knowledge, and that the FDA posts company announcements as a public service without endorsing the product or the company [1].

Eugia says it has not received any reports of adverse events related to this recall as of the announcement [1].

What the records show

The reason for the recall is listed in the FDA record as the presence of particulate matter identified as a glass particle inside the vial [1]. The company announcement describes a range of possible harms from injected glass. "There is a reasonable probability that use of product containing glass particulates can cause serious adverse health consequences," the company wrote, listing blockage and clotting in blood vessels, pulmonary embolism, permanent organ damage and death among them [1]. The notice also lists local vein irritation, inflammatory reaction, worsening of existing infections and allergic reactions as possible effects, and says that neonates, infants and patients with compromised organ function may be more susceptible [1].

The affected product can be identified by the following details on the label, per the company announcement [1]:

ItemDetail
ProductVancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL (Single Dose Vial)
BrandEugia
Lot number3VM26026A
ExpirationJUL 2028
Vial NDC55150-471-01
Carton NDC55150-471-10

The product is packaged in a 30 mL vial and packed as 10 vials per printed carton, with 10 cartons per shipper, according to the announcement [1]. Eugia shipped the entire lot to wholesalers nationwide from September 2, 2026, through September 15, 2026 [1].

Vancomycin hydrochloride for injection is described in the record as a glycopeptide antibacterial indicated in adult and pediatric patients, including neonates, for septicaemia, infective endocarditis, skin and skin structure infections, bone infections and lower respiratory tract infections [1].

The company says it is notifying distributors and customers by recall letters and arranging return or replacement of the recalled product [1]. Its notice tells wholesalers, hospitals, pharmacies, institutions and doctors with inventory from the lot to stop using it and quarantine it, and asks anyone who further distributed the lot to notify their accounts [1]. Hospitals and institutions are asked to inform healthcare professionals in their organizations [1].

Why it matters for EMS

Vancomycin is an intravenous antibiotic given in hospital and in some critical care transport and interfacility settings, and the recalled lot went to wholesalers across the country [1]. The risk described in the record is tied to injection of glass particulate, which the company links to vessel blockage, clotting and pulmonary embolism [1]. The announcement singles out neonates, infants and patients with compromised organ function as groups that may be more susceptible [1].

Because the recall reaches the user level, any agency, hospital pharmacy or transport program that stocks Eugia-brand vancomycin 1.25 g vials is within the scope of the recall letters the company says it is sending [1]. EMS clinicians follow local protocols and medical direction on how recalled stock is handled.

The record gives two company contact points. Medical questions or adverse event reports go to Eugia US LLC at 1-866-850-2876, Option 2, or pvg@aurobindousa.com, from 8:00 am to 5:00 p.m. Eastern, Monday through Friday [1]. Return questions go to Qualanex at 1-800-505-9291 or recall@qualanex.com, with live calls taken 7:00 am to 4:00 pm Central, Monday through Friday [1]. Adverse reactions or quality problems can also be reported to the FDA's MedWatch program online, by mail or by fax at 1-800-FDA-0178, and forms can be requested at 1-800-332-1088 [1].

What the records do not tell us

The record does not say how the glass particle was discovered, whether it was found by the company, a customer or a regulator, or how many vials were examined [1]. It does not state how many vials are in the lot or how many remain in distribution [1]. The announcement gives no information on which wholesalers or states received the product beyond the word "nationwide" [1].

The record does not say whether any other Eugia lots or other vial sizes of vancomycin were tested or are under review [1]. It does not identify a root cause for the glass particle or describe any manufacturing change [1]. The FDA record posts the company's announcement and does not include an independent FDA assessment or a recall classification [1]. No adverse events had been reported to the company as of the announcement date, but the record does not say whether any have been reported to the FDA directly [1].

What to watch

The company says it is sending recall letters to distributors and customers and arranging return or replacement of the recalled product [1]. The records do not give a date for completion of the recall or say when the FDA might post further information.

Questions readers ask

Which vancomycin lot is being recalled by Eugia?

Eugia US LLC is recalling lot number 3VM26026A of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL single-dose vials, with expiration JUL 2028. The vial carries NDC 55150-471-01 and the carton carries NDC 55150-471-10.

Why is Eugia recalling vancomycin for injection?

The company says particulate matter identified as a glass particle was found inside a vial. Its announcement says injected glass particles can cause blockage and clotting in blood vessels, pulmonary embolism, organ damage or death, as well as vein irritation and allergic reactions.

Has anyone been harmed by the recalled vancomycin?

Eugia US LLC says it has not received any reports of adverse events related to this recall as of its November 6, 2026 announcement.

Where was the recalled vancomycin distributed?

Eugia shipped the entire lot to wholesalers nationwide from September 2, 2026, through September 15, 2026. The recall extends to the hospital, healthcare facility and user level.

Sources

  1. FDA: Eugia US LLC (f/k/a Auro Medics Pharma LLC) Issues Voluntary Nationwide Recall of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL (Single Dose Vial) Due to Presence of Particulate Matter — fda.gov (2026-11-09). fda.gov/safety/recalls-market-withdrawals-safety-alerts/eugia-us-llc-f
How this story was made Drafted by Mepa8's AI newsroom from the 1 record listed above and nothing else. Before publication a verification program confirmed that every number and quotation in the story appears in those records, that no passage was copied from them, and that every cited link opens. Editor: Ryan Bolden, EMS professional, who reviews published stories and handles corrections. Medical review pending. How we use AI · Report an error

This is news, not medical advice. EMS clinicians: follow your local protocols and medical direction.

Free alerts

Know about the next recall or outbreak the day it is posted.

One email when a story touches EMS equipment, medications or public health. Plus the free 6am briefing if you want it.

Send me